Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
The way forward for greater manchester academic health science network ahsn
1. The way forward for
Greater Manchester
Academic Health Science
Network (AHSN)
Linda Magee, Chief Operating Officer | Manchester Academic Health Science Centre
2. Joint Working – why should we bother?
Understanding the regional view
"The way forward for the Greater
Manchester Academic Health Science
Network (GM- AHSN)"
Dr Linda Magee
MAHSC COO & Business Development Director
26 June 2013 ABPI Meeting
3. Overview
• Relationship between the Manchester
Academic Health Science Centre (MAHSC) and
GM-AHSN
• Our particular areas of interest and expertise
• Case Studies and Opportunities for
partnership working with industry – the good,
the bad and the ugly!
5. Salford CCG
Salford Royal
Manchester Mental
Health & Social Care
University Hospital
South Manchester
Christie
Central Manchester
University Hospitals
University of
Manchester
MAHSC
Members
6. MAHSC & GM-AHSN
• MAHSC described as the ‘beating heart’ of GM-
AHSN
• Many of the key assets to support delivery of the
GM-AHSN business plan are led, hosted or
supported by MAHSC members
• Domains will deliver reliable implementation of
selected NICE guidelines and iTAPP technologies
• Domains will also map to GM Clinical Networks
enabling effective advice and engagement of
clinical leadership
9. GMAHSN - Aims
• Improved health outcomes through systematic reduction of the number
of deaths amenable to healthcare (vast majority related to cardiovascular
risk factors)
• Deliver the safest healthcare through systematic reduction of harm from
medication error
• Systematic implementation of NICE guidance
• Systematic implementation of High Impact Innovations
• Deliver increased activity and output from invention and research
• Deliver education and training to create capability in measurement for
improvement, health informatics and digital technologies
• Create a climate for retention, development and growth of industry
10. Bio/pharma:
Systems Biology & ‘omics
Discovery Assets: MCCIR (AZ/GSL/UOM)
MCRC (AZ)
CDSS/MRC Fellowship Clin. Pharm.
COEBP
On e of top 3 UK biomed clusters,
significant specialised accommodation
(UMIC Innovation Centre, Medtech Centre,
CityLab, MediPark)
plus international airport and UK
competitive cost basis
Health Technology Hub:
(MIMIT/m health/e health)
supporting industry interface
And
significant commercialisation capability and
NHS IP Innovation Hub
( UMIP, Trustech)
Implementation science , safety , quality:
GM CLAHRC, NIHR Patient Safety Centre,
Haelo
UK leading Cancer Centre & Europe’s
largest Children’s Hospital
UK leading clinical research infrastructure:
imaging, bio-banking (UK Bio-bank); NIHR
GMCLRN, specialist Clinical Research
Facilities
& MAHSC Clinical Trials Unit
National Institute of Clinical Excellence
(NICE)
(Memorandum of Understanding)
University of Manchester in top three in UK
(RAE 2008)
MMU: Allied health, sports science &
rehabilitation
University of Salford : Allied health , digital
and media sector
University of Bolton : Health & Wellbeing
World class e-health infrastructure:
Salford integrated e-health record, NIBHI,
NW e Health
( ‘FARSITE’)
11. But our greatest asset is……..
Access to large, heterogeneous (3.5M and 11M in I hour
drive) but relatively stable population (all major diseases
areas and including areas of considerable deprivation)
12. Case Studies, Opportunities &
Challenges
• Partnership working with industry – the good, the bad and the ugly!
The Good
• GSK Salford Lung Study – first large, prospective, ‘real-world’ study on a pre-
licence medicine, across a large population within one geographical setting
• GSK/AZ – Manchester Collaborative Centre for Inflammation Research
• Health Technology Industries – med tech, e-health & m-health including focus on
supporting SMEs and links to wider community eg via Bionow
The Bad and the Ugly – no specifics!
• We need to understand each others expectations, drivers and required outcomes
otherwise disappointment, mistrust, poor outcomes
• Improving access to NHS and streamlining the process of engagement including
clear involvement with procurement process
• Working in true partnership – mutual benefit, respect and input
13. Global Biomedical Sector - Trends
Clinical
• Ageing population
• Chronic disease burden (70% cost for a few diseases) plus ‘frequent flyer’
disproportionately high cost to individual communities
• Personalised medicine (drug/diagnostic combinations)
Delivery
• Shift to local (home) from hospital based care – growing importance of adjunct
technologies to pharma eg mobile health technology
• Market has been defined by providers eg NHS but increasingly by individuals
Economic
• Imposition of price cuts on existing drugs
• Higher standards for reimbursement (UK risk share schemes) – need evidence of
value to healthcare systems in both developed & emerging markets
• Economic pressures to prescribe generics
• Value creation no longer reliant on R&D; value-added in manufacture &
distribution process
14. Challenges
• All now operating in difficult times
– Limited resources
– Ever greater efficiency required
– Increasing number and value of deliverables
– Increasing expectations of healthcare from the
patent and the public
– New modes of healthcare delivery requiring
different approaches
For all of us - more for less